You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 135 No. 12, December 1975 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL NOTES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (43)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Calcitonin Treatment of Hypercalcemia Due to Parathyroid Carcinoma

Synergistic Effect of Prednisone on Long-Term Treatment of Hypercalcemia

William Y. W. Au, MD

Arch Intern Med. 1975;135(12):1594-1597.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The inadequacy of long-term treatment for control of hypercalcemia is exemplified by the difficulties encountered in patients with recurrent parathyroid carcinoma. Among the approaches currently used, phosphate1,2 and mithramycin,3 although effective, may be associated with toxic effects, while calcitonin, which theoretically should be ideal for this problem because of its specific ability to inhibit parathyroid hormone-stimulated bone resorption and its lack of toxic effects, has been disappointing clinically because the initial effects are often not sustained.4 "Escape" from the inhibitory effects of calcitonin has been observed in organ culture5 as well as in vivo6 and may be due to changes in cellular responses to calcitonin rather than to the development of secondary increase in parathyroid hormone output,7 or to development of antibodies to calcitonin.8 Recent studies in organ culture showed that the escape of parathyroid hormone-stimulated resorption from calcitonin inhibition can be prevented by simultaneous treatment with glucocorticoids.9 This report . . . [Full Text PDF of this Article]


Author Affiliations

From the Department of Medicine, Rochester General Hospital and the departments of pharmacology and toxicology and medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY.


Footnotes

Received for publication Jan 23,1975; accepted March 22.

Reprint requests to 601 Elmwood Ave, Rochester, NY 14642 (Dr. Au).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1975 American Medical Association. All Rights Reserved.